Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCADIAN: Atovaquone + Chemoradiotherapy in NSCLC
NCT04648033Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Dec 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atovaquone in non-small cell lung cancer (NSCLC) (4 arms), sponsored by University of Oxford. Primary endpoint: Dose Limiting Toxicities at 25 weeks. Started Dec 2020; status: completed.
02
Drugs
atovaquone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04648033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648033.